Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Last trade$11.56
Day change-$0.21 (-1.78%)
Day range$9.23 – $12.36
Volume43,724
Market cap$13M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.06M
Price / earnings
—
Price / book
9.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.11×
Profitability
Earnings per share
-$28.62
Return on assets
-269.2%
Return on equity
-2,248.48%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.47×
Quick ratio
1.47×
Cash ratio
0.93×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$60.33M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for JSPR, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.07M
$5.14M
$4.48M
$4.78M
$5.88M
$5.65M
$5.51M
$5.43M
Research and development
$5.14M
$5.81M
$11.36M
$14.39M
$21.2M
$16.16M
$19.77M
$14.46M
Total operating expenses
$9.21M
$10.95M
$15.84M
$19.17M
$27.08M
$21.8M
$25.29M
$19.89M
Operating income
-$9.21M
-$10.95M
-$15.84M
-$19.17M
-$27.08M
-$21.8M
-$25.29M
-$19.89M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$2.76M
-$1.17M
-$9.1M
-$18.74M
-$26.72M
-$21.24M
-$24.32M
-$18.64M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.76M
-$1.17M
-$9.1M
-$18.74M
-$26.72M
-$21.24M
-$24.32M
-$18.64M
Net income attributable to common shareholders
-$2.76M
-$1.17M
-$9.1M
-$18.74M
-$26.72M
-$21.24M
-$24.32M
-$18.64M
EBITDA
-$9.19M
-$10.93M
-$15.55M
-$18.94M
-$26.82M
-$21.52M
-$25.04M
-$19.35M
Basic earnings per share
-$3.00
-$1.20
-$9.20
-$33.90
-$52.20
-$42.30
-$48.58
-$37.20
Diluted earnings per share
-$3.00
-$1.20
-$9.20
-$33.90
-$52.20
-$42.30
-$48.58
-$37.20
Recent news
Company coverage with links to the original publishers.
Jasper Therapeutics reported Q3 2026 results with $135.3 million in cash following its acquisition of Kira Pharmaceuticals and a $132 million funding round. The company completed enrollment in its Phase 2 IgA nephropathy study for vensobafusp alfa and expanded into additional kidney disease indications including FSGS and IC-MPGN. Interim data from the IgAN cohort is expected in Q4 2026. The company also effected a 1-for-30 reverse stock split and repurchased warrants.
Multiple M&A transactions and strategic reviews dominated the deal landscape. Jasper Therapeutics is exploring a sale or merger, Robinhood completed its $180 million acquisition of Canadian crypto platform WonderFi, Salesforce acquired Contentful, and Wellington Management purchased The Hartford Funds for $1.9 billion. Meanwhile, several companies including Long John Silver's franchisee and Please & Thank You filed for bankruptcy.
Jasper Therapeutics reported positive updated clinical data from its BEACON Phase 1b/2a study and open-label extension study of briquilimab for chronic spontaneous urticaria (CSU). The drug demonstrated rapid disease control with 67% of additional BEACON patients achieving complete response at 12 weeks and 75% of CSU participants in the extension study achieving complete response or well-controlled disease. Safety profile remained favorable with low-frequency, predominantly low-grade adverse events. The company plans to initiate a Phase 2b study in the second half of 2026.
Law firm investigating potential securities misconduct for Driven Brands and Jasper Therapeutics, alleging false statements about business performance and operational practices.
Law firm reminds investors of class action lawsuits against multiple companies, alleging false or misleading statements about business operations, financial conditions, and prospects.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.